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Abstract
Summary Anti-osteoporosis medication (AOM) use in pa-
tients exposed to glucocorticoids is thought to reduce frac-
tures. We found post-menopausal women using glucocorti-
coids for at least 90 days who also used an AOM within
90 days had 48 % fewer fractures by 1 year and 32 % fewer
fractures by 3 years compared to non-AOM users.
Introduction The purpose of this study is to explore the effec-
tiveness of adherence to quality measures by estimating the
effect of anti-osteoporosis medication (AOM) initiationwithin
90 days after chronic (≥90 days) glucocorticoid (GC) therapy
on osteoporotic fracture.
Methods A new-user cohort was assembled using the
MarketScan databases between 2000 and 2012. Included pa-
tients were female, age ≥50 at GC initiation, had a first GC fill
daily dose ≥10 mg and persisted for at least 90 days. During a
365-day baseline period, patients were excluded for prior GC
or AOM (bisphosphonate, denosumab, teriparatide) use, frac-
ture, or cancer diagnosis. Initiators of an AOM in the 14 days
pre- or 90 days post-GC fill were characterized as AOM users;
those without, AOM non-users. Follow-up began 91 days af-
ter GC fill with patients followed until fracture, loss of con-
tinuous enrollment, initiation of AOM by AOM non-users, or
end of study period. A propensity score was estimated for
AOM receipt using all measured covariates and converted to
a stabilized inverse probability of treatment weights (IPTW).
Weighted hazard ratios (HR) and associated 95 % confidence
intervals (95 % CI) were estimated using weighted Cox pro-
portional hazard models.
Results Of the 7885 women eligible for the study, 12.1 %
were AOM users. AOM use was associated with lower
fracture incidence: weighted HR of 0.52 (95 % CI 0.29,
0.94) at 1 year and weighted HR of 0.68 (95 % CI
0.47, 0.99) at 3 years.
Conclusions AOM initiation within 90 days of chronic GC
use was associated with a fracture reduction of 48 % at 1 year
and 32 % at 3 years.
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Introduction
Glucocorticoid-induced osteoporosis (GIO) is the most com-
mon secondary cause of osteoporosis [1, 2]. In the USA glu-
cocorticoids are estimated to be used by 1.2 % (∼1.5 million)
of persons aged ≥20, while worldwide estimates have ranged
between 0.5 and 0.9 % [3–7]. In the USA, between 1.4 and
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2.7 % of women aged ≥50 were current oral glucocorticoid
users with most having chronic (≥90 days) use [3]. Daily
glucocorticoids doses as low as 2.5 mg prednisone equiva-
lence are associated with an increased fracture risk, with the
most rapid loss of bone density occurring in the first 3 to
6 months after initiation [8–10]. Post-menopausal women
have higher fracture rates than men and are particularly sus-
ceptible to fractures after menopause [11]. Based on criteria
from the 2010 American College of Rheumatology (ACR)
guidelines for the prevention and treatment of GIO, 1.7 % of
US post-menopausal women were at risk for GIO between
2005 and 2010 [12]. Fractures due to GIO, particularly hip
fractures, increase mortality risk, health-care costs, risk of fu-
ture fractures, and comorbid conditions while decreasing pa-
tient’s quality of life [13, 14].
US clinical guidelines for the treatment and prevention of
GIO recommend anti-osteoporosis medications (AOM) in pa-
tients initiating or expecting to be on glucocorticoid therapy
for at least 90 days [2, 15–17]. The 2010 ACRGIO guidelines
include recommendations for treatment with AOMs—
bisphosphonates (alendronate, risedronate, and zoledronic ac-
id), or teriparatide—based on clinical risk factors [15]. These
four AOMs have been approved by the United States Food
and Drug Administration (FDA) for GIO and have demon-
strated efficacy in randomized controlled trials (RCT) for pre-
vention of bone loss [10, 13, 18]. Clinical guidelines have
recommended the use of denosumab, although it has not been
FDA approved for GIO [2, 17]. AOM treatment is expected to
reduce and prevent fractures in GIO based on RCTs of
alendronate and risedronate which demonstrated attenuated
bone mineral density (BMD) loss (primary endpoint) and a
reduction in vertebral fractures (secondary endpoint)
[10, 19, 20]. To date, no GIO RCTs have used fracture
as the primary endpoint.
Two GIO-related quality measures have been endorsed by
the National Quality Forum based on expert opinion and re-
sults of the aforementioned RCTs; within 180 days of initia-
tion of a glucocorticoid, patients should receive the following:
(1) treatment with an AOM or (2) a diagnostic dual energy X-
ray absorptiometry (DXA) scan [21, 22]. To our knowledge,
no clinical studies have attempted to estimate the effect of
AOM initiation on fracture risk based on receipt of quality
measure care in new glucocorticoid users.
Two 2013 observational studies produced conflicting re-
sults related to use of AOM in GIO [23, 24]. A population-
based registry conducted in Manitoba, Canada, reported that
AOM or DXA use within 180 days of chronic glucocorticoid
initiation increased the odds of fracture by 30%within 3 years
[23]. The second study was a retrospective cohort study of
bisphosphonate users, reporting a decrease in fracture risk at
12 months [24]. Both studies’ estimates may be subject to
selection bias by including long-term users of therapy, or con-
founding by disease severity and/or underlying fracture risk
according to gender and age. These conflicting findings have
resulted in persistent questions regarding the effectiveness of
preventive AOM treatment in GIO despite evidence of bene-
ficial effects on BMD [25].
With reports of 1.7 % of the US post-menopausal popula-
tion at risk for GIO, it is important to determine if AOM
treatment concordant with currently endorsed quality mea-
sures reduces fracture risk in GIO. To investigate the associa-
tion between AOM use and fracture risk among those at risk
of GIO, we conducted a retrospective cohort study of women
aged 50 years and older newly initiating chronic glucocorti-
coids based on administrative claims data. Specifically, we
aimed to estimate the effect of AOM initiation within 90 days
after chronic glucocorticoid initiation on osteoporotic fracture.
Materials and methods
Data source
We used MarketScan (Truven Health Analytics, Ann Arbor,
MI) Commercial Claims and Encounters (CCAE) and Medi-
care Supplemental Coordination of Benefits (COB) databases
(January 1, 2000–December 31, 2012) for this study. These
combined databases are de-identified and contain information
from a large population of patients with employer-provided
insurance residing in all 50 states and the District of Columbia.
The MarketScan databases capture individual-level clinical
utilization, expenditures, and enrollment across inpatient, out-
patient, prescription drug, and carve-out services from a wide
selection of employer-sponsored health plans. In 2011 the
databases contained data on approximately 60million covered
lives [26]. The Institutional Review Board at the University of
North Carolina at Chapel Hill determined that this study did
not constitute human subjects research and so did not require
IRB approval.
Study design and population
We conducted an administrative claims-based retrospective
cohort study of the impact of AOM initiation on GIO-
fracture risk in women aged 50 and older on ≥10 mg predni-
sone equivalent glucocorticoids. We define AOMs as
alendronate, ibandronate, risedronate, zoledronic acid,
teriparatide, or denosumab. We have included denosumab in
our AOMs based on an ongoing phase III trial of its use for
prevention of bone loss in glucocorticoid treatment patients,
while ibandronate has been shown to significantly increase
lumbar spine and total hip BMD in glucocorticoid patients
[27, 28]. Our study employs a new user design, focusing on
incident rather than prevalent users of glucocorticoids and
AOM, as prevalent users may have exceeded the quality mea-
sure period and likely have differing baseline characteristics
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and fracture risks than new users [29]. The date of initial
glucocorticoid fill is considered the index date, the 365 days
pre-index are considered the baseline period, with 14 days
pre- and 90 days post-index considered the quality measure
period (see Fig. 1).
We identified women age ≥50 with a new outpatient phar-
macy dispensing of a ≥10 mg prednisone equivalent oral glu-
cocorticoid that did not fill either a glucocorticoid or AOM
during the baseline period or at any other point prior to the
index date [30, 31]. Patients were required to have continuous
health plan enrollment during both the baseline and quality
measure periods. We required patients’ first period of gluco-
corticoid use to be ≥90 days including the index date; we
allowed a gap of up to 30 days between the last supplied
day and first date of new fill to still be considered continuous
use. We used International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9), Common Procedure
Terminology (CPT), or Healthcare Common Procedure Cod-
ing System (HCPCS) codes to identify patient characteristics,
inclusion, and exclusion criteria during the baseline window.
Patients with a diagnosis claim for cancer (ICD-9 140-208) at
any time during their enrollment prior to the index date were
exc luded due to cancer - re la ted f rac tures be ing
pathophysiologically different from osteoporotic fractures
[31, 32]. If no medication dispensing of any kind was ob-
served during baseline, the patient was excluded due to the
possibility of missing pharmacy claims during the baseline
which could cause misclassification. As prior fractures are
associated with future fracture risk, we excluded patients with
any fractures (ICD-9 733.1–733.19 or 800–829) during base-
line and the quality measure period. Follow-up began at the
end of the quality measure period (day 91) and fractures dur-
ing the quality measure period represented outcomes that were
unlikely to have been affected by AOM use and may have
prompted AOM initiation. Further details of inclusion/
exclusion are presented as Fig. 2.
Exposure assessment
We assessed AOM initiation during the quality measure peri-
od, which extended from 14 days prior to the index date to
90 days after. Although clinical guidelines recommend initia-
tion of an AOM within 180 days of GC initiation, our main
analysis uses a 90-day exposure period to reduce attrition due
to loss of continuous enrollment or early fracture. To address
the current clinical quality measure, we conducted a sensitiv-
ity analysis using 180 days as the quality measure period (see
“Sensitivity Analyses” below). Patients who filled an AOM
during the quality measure period are referred to as AOM
users, and those without any use during the quality measure
period are referred to as AOM non-users. The 14 days prior to
index glucocorticoid fill are considered part of the quality
measure period due to the assumption that these patients
were being treated with AOM in the anticipation of
glucocorticoid use.
Covariate assessment
Baseline characteristics were assessed during baseline
based on ICD-9 and CPT codes including a diagnosis
of osteoporosis, continuous age, region of health plan,
type of insurance, year of index fill, conditions associ-
ated with secondary osteoporosis per the 2004 Surgeon
General’s Report, Charlson comorbidity index, condi-
tions associated with falling, DXA scan use, healthcare
utilization (number of outpatient visits and number of
inpatient admissions), calcitonin, raloxifene, and hor-
mone therapy use [33–36]. Codes used to define each
of the covariates are presented in Supplementary Table 1
with specific conditions associated with secondary oste-
oporosis and falling listed. Selected covariates are pre-
sented in Table 1, with a full listing presented in Sup-
plementary Table 2.
Outcome assessment
The primary fracture outcome is defined as a fracture at the
hip, pelvis, humerus, wrist, or spine (vertebral, cervical, lum-
bar, and/or thoracic fractures). The specific codes are available
in Supplementary Table 3 [37, 38]. This fracture definition is
based on two separate published fracture algorithms, with
ICD-9 diagnoses of hip, humerus, and wrist fractures which
Fig. 1 Study schematic
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required having accompanying CPTcodes for treatment with-
in 30 days [37]. Our use of all four spinal sites and associated
codes were based on fractures at these sites likely being asso-
ciated with osteoporosis [38].
Follow-up began the day after the end of the quality mea-
sure period (91 days after index-fill). Patients were followed
until fracture, loss of health plan enrollment, end of
study period (December 31, 2012), or fill of an AOM
by a participant who was designated an AOM non-user
at baseline. Analyses were administratively censored at
1 and 3 years in separate analyses, if no events were
present. We present event rates per 1000 person-years
for fractures in both the AOM users and AOM non-
users as well as AOM use by non-AOM users as well
as mean (standard deviation [SD]) days follow-up at a
maximum of 1 and 3 years for both groups.
Statistical methods
To control confounding by measured characteristics, we esti-
mated a propensity score for receipt of an AOM within the
quality measure period using logistic regression models in-
cluding all measured covariates [39, 40]. The resulting pro-
pensity scores were the probability of receipt of an AOM
based on all the measured covariates. We then converted the
propensity score into stabilized inverse probability of treat-
ment weights (IPTW). When IPTW weights are applied, a
pseudo-population is created where the measured covariates
are not associated with the outcome, and both the treated and
untreated groups are standardized to the overall population
[39]. Advantages of IPTW weighting includes retention all
study patients and estimate of an average treatment effect in
the whole population of eligible patients.
Fig. 2 Inclusion and exclusion
diagram. GC oral glucocorticoid,




ICD-9 (140-208.xx); fracture in
the preceding 365 days or within




Baseline differences between the treatment groups were
assessed using Student’s t tests for continuous and chi-
square tests for categorical variables to determine if differ-
ences in covariate distributions between AOM users and
non-users were present (presented in Supplementary Table 3).
We conducted a modified intent-to-treat (ITT) by censoring at
AOM initiation in baseline non-users. The modified ITT was
used as subsequent initiation was thought to lower fracture
risk from that point forward. To address the use of the modi-
fied ITT, a true ITT was also undertaken (see “Sensitivity
Analyses”). Hazard ratios (HR) and 95% confidence intervals
(95 % CI) were estimated using Cox proportional hazard
models. HRs are reported for unadjusted, adjusted for all mea-
sured covariates, and IPTW-weighted analyses. All analyses
were performed with SAS 9.3 (SAS Institute, Cary, NC).
Sensitivity analyses
We undertook three types of sensitivity analyses associated
with this study. First, as our primary analysis uses a quality
measure period of 90 days rather than the quality measure-
recommended 180 days, we varied the length of the quality
Table 1 Selected demographics of patients who filled (AOM users) or did not fill (AOM non-users) an anti-osteoporosis medication within 90 days of
starting a glucocorticoid (2000–2012)
Characteristic, N (%) unless otherwise specified Crude population Weighted population
AOM users AOM non-users AOM users AOM non-users
N 952 6933 937 6937
Age, mean (SD) 67.5 (10.6) 66.6 (11.4) 67.0 (11.4) 66.7 (11.3)
50–59a 260 (27.3) 2421 (34.9) 296 (31.6) 2360 (34.0)
60–69a 276 (29.0) 1839 (26.5) 256 (27.4) 1867 (26.9)
70–79a 270 (28.4) 1535 (22.1) 221 (23.6) 1576 (22.7)
80+a 146 (15.3) 1138 (16.4) 163 (17.4) 1135 (16.4)
In 365 days prior to index
Osteoporosis 80 (8.4) 222 (3.2) 41 (4.3) 272 (3.9)
Diabetes mellitus (types 1 and 2) 117 (12.3) 1182 (17.0) 138 (14.8) 1143 (16.5)
Central adiposity 16 (1.7) 244 (3.5) 27 (2.9) 229 (3.3)
Inflammatory bowel disease 12 (1.3) 271 (3.9) 49 (5.3) 249 (3.6)
Rheumatoid arthritis 135 (14.2) 1078 (15.5) 128 (13.7) 1066 (15.4)
Stroke 90 (9.5) 621 (9.0) 83 (8.9) 626 (9.0)
Congestive heart failure 76 (8.0) 697 (10.1) 84 (9.0) 677 (9.8)
Asthma/COPD 158 (16.6) 1352 (19.5) 175 (18.7) 1328 (19.1)
Proton pump inhibitors 257 (27.0) 1951 (28.1) 280 (29.9) 1943 (28.0)
Anticonvulsants 93 (9.8) 868 (12.5) 133 (14.2) 847 (12.2)
Calcitonin 11 (1.2) 86 (1.2) 10 (1.1) 86 (1.2)
Hormone replacement therapy 198 (20.8) 1347 (19.4) 186 (19.9) 1364 (19.7)
Raloxifene 23 (2.4) 124 (1.8) 21 (2.2) 131 (1.9)
DXA 177 (18.6) 708 (10.2) 111 (11.8) 788 (11.4)
Charlson Comorbidity Score
0 811 (85.2) 5682 (82.0) 777 (83.0) 5716 (82.4)
1 27 (2.8) 212 (3.1) 28 (3.0) 210 (3.0)
2 55 (5.8) 498 (7.2) 71 (7.6) 487 (7.0)
3–5 52 (5.5) 431 (6.2) 51 (5.4) 422 (6.1)
≥6 7 (0.7) 110 (1.6) 10 (1.0) 103 (1.5)
In 90 days post-index
Osteoporosis 100 (10.5) 151 (2.2) 34 (3.6) 225 (3.2)
DXA 264 (27.7) 626 (9.0) 115 (12.3) 787 (11.3)
All demographic variables are listed in Supplementary Table 3
COPD chronic obstructive pulmonary disease, DXA dual energy X-ray absorptiometry
a Age by decade has been presented here for descriptive purposes but is not included in the propensity score
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measure period to determine its effect on treatment estimates.
Analyses using 30-, 60-, 120-, 150-, and 180-day quality mea-
sure periods were conducted using the same fracture definition
and exclusion criteria as the main analysis. Second, to deter-
mine the sensitivity of our results to the fracture definition, we
employed varying fracture definitions, including (1) compos-
ite of hip, pelvis, humerus, or wrist fractures with associated
CPTs (non-spine); (2) spine fractures; (3) vertebral fractures
alone; and (4) spine fractures excluding cervical fractures.
Third, as we employed a modified ITT for the primary analy-
sis, we conducted a true ITT analysis by only censoring non-
AOM users for loss of enrollment or the end of the study
period. To better visualize the effect of these multiple esti-
mates, sensitivity analysis results are presented as forest plots.
Results
There were 7885 women who met all inclusion criteria (see
Fig. 2). Among those, 952 patients (12.1 %) were classified as
AOM users. Bisphosphonates accounted for 95.5 % of all
AOMs initiated during this quality measure period
(alendronate 67.5 %, ibandronate 4.1 %, risedronate 26.9 %,
zoledronic acid 0.9 %) with teriparatide accounting for the
remaining 0.5 %. Selected baseline characteristics of AOM
users and non-users before and after weighting are presented
in Table 1 with all baseline characteristics presented in Sup-
plementary Table 3. Before weighting both during baseline
and quality measure period, AOM users had osteoporosis di-
agnoses more often (baseline 8.4 vs. 3.2 %, quality measure
period 10.5 % vs. 2.2 %) and received DXAs more often
(baseline 18.6 vs. 10.2 %, quality measure period 27.7 vs.
9.0 %). AOM non-users were more likely to have a diagnosis
for asthma/chronic obstructive pulmonary disease (COPD)
(16.6 vs. 19.5 %) and based on region, women in the southern
region of the US used AOMs less often (23.9 vs. 28.2 %).
Although the mean ages were similar (AOM users [67.5] vs.
AOMnon-users [66.6]) a greater proportion of non-users were
aged 50–59 (27.3 vs. 34.9 %), while a greater proportion of
those aged 70–79 were AOM users (28.4 vs. 22.1 %). After
weighting, all measured covariates were balanced between the
treatment groups, except for barbiturate use (0.8 vs. 0.2 %),
inflammatory bowel disease (5.2 vs. 3.6 %), and end-stage
renal disease (4.5 vs. 3.2 %).
With a maximum of 1-year follow-up, fractures occurred at
a rate of 20.1 per 1000 person years in AOM users, 29.7 per
1000 person years in AOM non-users, and 129.7 per 1000
person years for AOM use in non-AOM users. Mean
follow-up time with a maximum at 1 year was 300.5 days
(SD 109.1) for AOM users and 274.6 days (SD 123.8) for
non-users. AOM use was associated with a decreased fracture
risk: unadjusted HR=0.68 (95 % CI 0.41, 1.14), adjusted
HR=0.67 (95 % CI 0.39, 1.15), and weighted HR=0.52
(95 % CI 0.29, 0.94) at 1 year (Table 2).
With a maximum of 3 years follow-up, fractures occurred
at a rate of 21.4 per 1000 person years in AOM users, 27.5 per
1000 person years in AOM non-users, and 91.2 per 1000
person years for AOM use in non-AOM users. Mean
follow-up time with a maximum of 3 years was 639.8 days
(SD 392.0) for AOM users and 541.2 days (SD 397.1) for
AOM non-users. AOM use was associated with a slightly
more attenuated reduction in fracture risk: unadjusted HR=
0.79 (95 % CI 0.56, 1.11), adjusted HR=0.78 (95 % CI 0.54,
1.12), and weighted HR=0.68 (95 % CI 0.47, 0.99) (Table 2).
Our sensitivity analyses varying the length of the quality
measure period found that in all time period lengths, AOM use
was associated with lower fracture rates at both 1 and 3 years
(see Supplementary Figs. 1 and 2). Specifically, weightedHRs
for 60 and 120 day quality measure periods indicated AOM
use within these time periods reduced fracture rates at 3 years.
Of note, after accounting for exclusions at 180 days, AOMs
were filled by 16.6 % (1174/7093) of patients without a frac-
ture by 180 days. Separating the fracture definition in non-
spine, spine, vertebral alone, and without cervical yielded pro-
tective weighted HRs at both 1 and 3 years for all three frac-
ture definitions (see Supplementary Figs. 3 and 4). The third
sensitivity analysis using a true ITT design is presented as
Supplementary Figs. 5 and 6. We found that when patients
were only censored at loss of continuous enrollment or end
of the study period, weighted estimates were more protective
than the main analysis at both 1 and 3 years.
Excluded patients
Patients who were excluded from the analysis due to fractures
in the quality measure period included 174 women, equivalent
to 2.2 % of the total study population from our analysis (refer
to Fig. 1). Vertebral fractures were the exclusion for 10.3 % of
this population, with an additional 7.5 % having hip fractures,
and the remaining 82.2 % with a fracture at another site. The
mean age was 70.1 (11.3)years with 4.6 % having a diagnosis
of osteoporosis and 9.8 % having a DXA prior to GC initia-
tion. A total of 34.8 % of the excluded population initiated an
AOM within 90 days, with 41.7 % of these patients filling an
AOM prior to fracture.
Discussion
In this study, women ≥50 who initiated glucocorticoid therapy
at ≥10mg daily for 90 days or more and filled an AOMwithin
a quality measure period 14 days prior or up to 90 days after
initiation showed a fracture risk reduction of 48 % at 1 year
and 32 % at 3 years compared to patients who did not fill an
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AOM. Our results suggest initiation of AOM therapy within
90 days can effectively reduce fracture risk for GIO patients.
These results represent an estimate of the longer-term efficacy
of AOM initiation in older US women without known previ-
ous glucocorticoid or AOM use initiating high-dose glucocor-
ticoids. With only an additional 5 % of patients without frac-
ture filling an AOM at 180 days compared to 90 days, our
results suggest that adherence to the 180-day AOM prescrib-
ing goal in current clinical quality measures can help reduce
fracture in the high-risk population of chronic oral GC users.
We report a reduction in fracture risk similar to estimates by
Thomas et al., but in the opposite direction of Majumdar et al.
[23, 24]. Majumdar et al. found that compared to long-term
oral GC users without documented AOM or DXA, those with
documentation of receipt of an AOM or DXA scan within
180 days of initiation of ≥10 mg prednisone equivalent dose
was associated with an increased fracture HR at 1 and 3 years
[23]. However, Majumdar et al. did not account for differing
baseline fracture risks as evidenced by including all ages and
genders in the study population, nor did they account for fu-
ture fracture risk due to previous fracture, likely causing con-
founding by indication. Also, Majumdar et al. defined high-
quality GIOP care by a composite endpoint of a BMD test or a
dispensing of prescription osteoporosis medications within
6 months of a new long-term systemic GC initiation. If most
individuals in the GIO care group received a BMD test but not
osteoporosis medication, similar fracture rates would be ex-
pected in the test vs. comparison group. Our study focused
only on treatment to estimate outcomes associated with ther-
apeutic interventions, not diagnostic testing.
Our study used the same database as Thomas et al., though
their study only included patients who were concurrently
using glucocorticoids and bisphosphonates [24]. Thomas
et al. required bisphosphonate use prior or concurrent to glu-
cocorticoid use which may not be representative of common
clinical use and likely measures the effect of bisphosphonate
continuation with glucocorticoid use, rather than the effect of
AOM use after glucocorticoid initiation. Similarly, the com-
parison of fractures at 3 months to fractures at 12 months does
not address if bisphosphonates use is more effective than non-
use, only that long-term use of bisphosphonates are effective
in reducing fractures.
Previous estimates of the prevalence of AOM use with
chronic glucocorticoids have ranged from 14.5 to 50 %, sug-
gesting our study population received AOM at a lower rate
(12.1 %) compared to other study populations [6, 12, 41, 42].
This likely is due to our exclusion of prevalent fragility frac-
tures and prevalent glucocorticoid users, which, if included,
may have increased the treatment percentage due to higher
baseline fracture risks. AOM users received DXAsmore often
in the year prior as well as the 90 days post glucocorticoid
initiation compared to AOM non-users which is similar to
DXA utilization in the Global Longitudinal Study of Osteo-
porosis in Women (GLOW) study [43]. All patients in this
analysis based on a prednisone equivalent dose >7.5 mg
would be recommended an AOM by the 2010 ACR guide-
lines, though only 24.8 % of this at-risk population has been
reported as treated [12, 15]. In our current study, we observed
a similarly low initiation rate (12.1 %) in women who were
new glucocorticoid initiators previously unexposed to AOMs.
Although current US quality measures measure receipt of an
AOM within 180 days of glucocorticoid initiation, we found
that after exclusion of prevalent fractures, only an additional
5 % of patients filled an AOM at 180 days compared to
90 days. Additionally, the effect measure estimate was atten-
uated as the length of the period increased, likely due to the
exclusion of early events in the longer windows. For example,
when using a 180-day window, an additional 1113 patients
would have been excluded from the analysis for either fracture
or loss of continuous enrollment, further reducing the sample
size. This finding suggests that most clinicians who adhere to
GIO quality measures do so shortly before or after the patient
Table 2 Fracture rates associated with AOM (anti-osteoporosis medication) use within 90 days of chronic glucocorticoid initiation
















AOM users 1 year 20.1 N/A 306.3 (106.1) 0.68 (0.41, 1.14) 0.67 (0.39, 1.15) 15.3 N/A 300.5 (109.1) 0.52 (0.29, 0.94)
AOM non-users 1 year 29.7 129.7 274.8 (123.4) REF REF 29.6 136.3 274.6 (123.8) REF
AOM users 3 years 21.4 N/A 680.8 (398.5) 0.79 (0.56, 1.11) 0.78 (0.54, 1.12) 18.4 N/A 639.8 (392.0) 0.68 (0.47, 0.99)
AOM non-users 3 years 27.5 91.2 539.7 (395.6) REF REF 27.3 94.8 541.2 (397.1) REF
Rate is event per 1000 person years
HR unadjusted hazard ratio, aHR hazard ratio adjusted for all available covariates, wHR stabilized inverse probability of treatment weighted (IPTW)
hazard ratio
a AOM non-users were censored at use of AOM after the end of the QM period
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initiates GC use. Therefore, protocols to improve GIO care
may be most successful if they are implemented at the clinic
visit when the first GC prescription is issued.
Our main analysis defined osteoporotic fracture as those at
the hip, pelvis, humerus, wrist, and spine showing a signifi-
cant reduction in fracture risk at 1 and 3 years. However, there
is no definitive, validated definition for osteoporotic fracture
in administrative claims data. The algorithms used in this
analysis have previously been published and, in the case of
the non-spine codes, have been validated [37, 44]. We includ-
ed the spine sites in the analysis primarily due to the secondary
findings of reduction in vertebral fractures in RCTs. The sites
and codes are based on fractures that are regarded as likely due
to osteoporosis [38]. All four fracture definitions in the sensi-
tivity analysis produced similar protective estimates at both 1
and 3 years, though less precise due to the small number of
events. When the outcomes were combined, the increased
number of events allowed increased precision. The direction-
ality of our sensitivity analysis strengthens our conclusions of
a protective effect for AOM use.
Our study possessed several limitations that should be not-
ed. The MarketScan databases include both commercially in-
sured patients and patients with Medicare supplemental insur-
ance who may not be representative of the Medicare, unin-
sured, or publically insured populations. Though, our use of
IPTW weights reduced confounding which would have been
associated with patient location. Our estimates likely have
some unmeasured confounding present as the MarketScan
database did not have clinical variables such as bone mineral
density, frailty, or functional impairment available which
could have contributed to the prescription of AOMs and future
fracture risk. Our study methodology does not account for any
additional variability due to persistence or adherence to AOM,
or cumulative dose or duration of glucocorticoid therapy.
However, we viewed a modified ITT analysis as the most
conservative estimate of AOM effectiveness as subsequent
AOMwas thought to reduce future fracture risk. Additionally,
our sensitivity analyses using a true ITT produced more pro-
tective HRs than the main analysis, suggesting validity of our
main analysis results. Exposure is based on AOM fill within
90 days, which may introduce selection bias due to all patients
having to live and be without fracture for the entire quality
measure period to be included in the study. However, we view
this exclusion as essential for comparable fracture risks at the
end of the quality measure period and describe the women
who had fractures in the 90 days post-index in the results.
Due to small sample sizes, stratified analyses of individual
AOM agents were not conducted. Because we used adminis-
trative claims, patient’s prior exposure to glucocorticoids or
AOMmay not be accurate. To minimize misclassification, we
excluded all patients who had a fill of either of these therapies
recorded in the database prior to index fill regardless if it fell
within the baseline period [31]. Exposure was based on first
fill daily dose, which may not be indicative of daily dose for
the duration of use. Patients who had fractures greater than
1 year prior to glucocorticoid initiation were not identified and
excluded in this analysis, therefore there may be patients with
prior fractures in this analysis. Although the primary aim of
our paper was to examine fracture outcomes in glucocorticoid
users receiving AOM versus patients not receiving AOM,
future studies may also want to consider the effect of AOM
initiation on health-care resource utilization and patient char-
acteristics associated with AOM initiation. A composite frac-
ture outcome was used for the main analysis and was based on
two previously defined algorithms which may not capture all
osteoporotic fractures and which might have included trau-
matic fractures. We could not verify menopausal status in
these databases; and providers may have been less willing to
prescribe AOM for women in their 50s who were premeno-
pausal. Our study results are generalizable towomen≥50years
of age who are new initiators of glucocorticoids and AOMs.
Patients excluded from our analysis due to fractures within
90 days of glucocorticoid initiation represent a population
who would benefit from AOM treatment but were not ana-
lyzed; to account for this at-risk population, we describe the
population characteristics in the “Results” section. Lastly, our
study period spanned 12 years wherein AOM and guidelines
for AOM treatment have changed; this may result in differen-
tial treatment based on when the glucocorticoid was initiated.
Based on our results, AOM fill within 90 days of initiating
≥10 mg daily glucocorticoids was associated with a 48 %
reduction at 1 year and 32 % at 3 years for osteoporotic frac-
ture, suggesting that treatment for GIO based on quality mea-
sures can be effective in preventing fractures. Less than 12 %
of glucocorticoid initiators without prior AOM treatment
filled an AOM during the 90 days after glucocorticoid initia-
tion, continuing to demonstrate a care gap in glucocorticoid-
induced osteoporosis. Our findings suggest that to reduce frac-
tures, quality measures for GIO may be more effective if
AOM treatment is recommended within 90 days rather than
180 days. Continued screening, assessment of fracture risk,
and appropriate treatment are essential to prevent fractures in
GIO. To further close the care gap in GIO, clinicians should
consider initiating AOM therapy if they believe their patients
may use a glucocorticoid for 90 or more days.
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